
Triple-receptor agonist · 40mg formulation · Highest dose in the Retatrutide range
Retatrutide is a next-generation triple agonist compound that targets GLP-1, GIP, and glucagon receptors simultaneously. The RT40 Protocol delivers this triple-action mechanism at a 40mg dose — the highest formulation in the Retatrutide range.
By activating all three receptor pathways, the protocol supports comprehensive metabolic regulation, appetite signalling, energy expenditure, and body composition goals that single or dual agonists cannot address alone.
The RT40 formulation is intended for established clients who have progressed through the lower-dose Retatrutide formulations (RT10 → RT20 → RT30) under expert guidance. Progression to RT40 should always be reviewed with our expert team.
Every SHIFA LABS protocol is manufactured using advanced synthesis techniques within controlled laboratory environments. Carries ≥99.9% purity certification and full batch-specific QA documentation.
Our experts will help ensure the RT40 Protocol is the right formulation for your metabolic goals.